NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Ltd. - Ordinary Shares (NCEL)
Company Research
Source: PR Newswire
Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership teamZURICH, Jan. 29, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon.The updated corporate deck reflects NewcelX's sharpened strategic focus on its lead cell therapy programs for Type 1 Diabetes, highlighting recent scientific progress, clinical development priorities, and the Company's differentiated approach to restoring endogenous insulin production through regenerative medicine.In addition, the presentation introduces several highly experienced and internationally recognized additions to NewcelX's Scie
Show less
Read more
Impact Snapshot
Event Time:
NCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCEL alerts
High impacting NewcelX Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NCEL
News
- NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences [Yahoo! Finance]Yahoo! Finance
- NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune SuppressionPR Newswire
- NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory BoardPR Newswire
- NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China [Yahoo! Finance]Yahoo! Finance
- NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in ChinaPR Newswire
NCEL
Sec Filings
- 1/29/26 - Form 6-K
- 1/12/26 - Form 6-K
- 1/5/26 - Form 6-K
- NCEL's page on the SEC website